Pemetinib/Monthly Dosage Guidelines for Pemetinib

Pemigatinib/Pemigatinib is a targeted kinase inhibitor that can effectively block the biological activity of specific protein kinases. The drug is specifically approved to treat adult patients with cholangiocarcinoma that has metastasized or cannot be removed with surgery. It is usually used after a patient has been treated with other drugs and the cancer shows a specific abnormality in the FGFR2 gene. In addition, pemetinib is also a treatment option for patients with myeloid/lymphoid neoplasms (MLNs) who have relapsed or failed to respond to standard treatments and whose cancers have specific FGFR1 gene abnormalities.

The U.S. Food and Drug Administration (FDA) has approved the use of pemetinib in the treatment of cholangiocarcinoma through the accelerated approval process. Although clinical studies have shown that some patients respond well to pemetinib, more research is needed to verify its long-term effects. In the treatment plan, the recommended daily dose of pemetinib is 13.5 mg, and patients need to take it continuously for 14 days and then stop taking it for 7 days, forming a 21-day treatment cycle. Treatment will continue until disease progression or intolerable drug toxicity occurs.

The common dosage specifications of pemetinib are4.5mg 14 tablets, 9mg 14 tablets and 13.5mg 14 tablets. If the patient is using 13.5mg 14 tablets, then theoretically he needs about two boxes per month. However, actual dosage may vary based on individual patient differences and responses. If adverse reactions occur, doctors may adjust the dose to ensure patient safety and effectiveness. Therefore, determining the monthly dosage of pemetinib requires comprehensive consideration of the patient's specific condition, physician recommendations, and the strength of the drug purchased. During treatment, patients should maintain close communication with their doctors and report any physical changes at any time to ensure optimal and safe treatment results.